Navigation Links
CleveMed Receives $1.23 Million in NIH Funding to Develop a System to Augment Deep Brain Stimulation Programming in Parkinson's Disease
Date:10/7/2008

CLEVELAND, Oct. 7 /PRNewswire/ -- Cleveland Medical Devices Inc. (CleveMed) announced it has been awarded $1.23 million in NIH SBIR FastTrack funding from the National Institute on Aging to develop ParkinTune(TM), a system to augment stimulator programming in deep brain stimulation (DBS) procedures for Parkinson's disease (PD). CleveMed is collaborating with clinicians at the Center for Neurological Restoration of the Cleveland Clinic Foundation, a world renowned, pioneering DBS surgery center.

"Clinical tools are needed to improve deep brain stimulation procedures and patient outcomes," said Dr. Jerrold Vitek, Director of the Cleveland Clinic Foundation Neuromodulation Research Center and grant collaborator. "Assisting neurologists by objectively capturing and tracking motor performance in response to stimulation settings with a compact wireless device should show efficacy in optimizing patient outcomes in Parkinson's disease."

DBS is a surgical procedure for treating PD motor symptoms, such as tremor, bradykinesia (slowed movements) and rigidity, when medication is no longer effective. During surgery, an electrode is implanted in a targeted location in the brain. Once inserted, the stimulator intensity, frequency and duration are programmed. This programming is also necessary in several outpatient sessions over a period of months post surgery. Each time the stimulator settings are changed the patient's motor symptoms are evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) motor exam, a subjective evaluation clinicians use to assess PD motor symptoms. The process is repeated multiple times until optimal stimulator parameters are found which minimize motor symptoms. Utilizing an automated technology platform to objectively quantify Parkinson's motor symptoms and suggest optimized stimulation settings based on those measurements may reduce the time and cost of programming sessions as well as improve patient outcomes.

"CleveMed has previously demonstrated efficacy in objectively monitoring movement disorder motor symptoms," said Dr. Joseph Giuffrida, Director of CleveMed's Division of Movement Disorders and grant principle investigator. "Expanding this technology and knowledge to DBS programming should provide neurologists with an innovative tool for understanding specific neural mechanisms of DBS on motor control."

The objective is to further commercialize Kinesia(TM), a clinical device currently on the market for monitoring upper extremity PD symptoms, for a new area of use which will aid clinicians with stimulator programming during DBS surgery and post surgical tuning sessions to ensure optimal control of motor symptoms has been achieved. The technology to be developed will further strengthen our product portfolio and leading position in the area of ambulatory monitoring for movement disorders. The system will utilize a wireless patient unit worn on the hand that will transmit the kinematic motion data to a nearby laptop. The laptop will display objective symptom information and suggested stimulation settings to help the clinician rapidly program stimulation parameters. By providing repeatable and objective biokinetic data of patient symptoms along with visual examination, ParkinTune may reduce time and costs associated with DBS surgeries and outpatient programming sessions as well as increase patient comfort and overall outcomes.

About CleveMed - CleveMed was founded with the goal of developing innovative telemetry devices for a variety of medical applications. Today, CleveMed is developing and pioneering the use of novel wireless monitoring systems for high growth neurology and rehabilitation applications, including brain monitoring, sleep disorders and movement disorders. Through these innovations, CleveMed has developed a growing range of products that address the needs of the medical, research and academic communities.


'/>"/>
SOURCE CleveMed
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DxTech Receives Development Funding
2. Texas Health Resources Receives Grant From Robert Wood Johnson Foundation to Support Prevention of Family Violence
3. MedPlexus Electronic Health Record Receives 08 CCHIT Certification
4. Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter
5. Updated MD-CARE Act Receives Final Congressional Approval
6. Diabetes Research and Awareness Receives Big Boost Thanks to Generous Gift from Thomas McInerney
7. Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation
8. Partnership for Peak Healthcare Performance Receives Grant from Aetna Foundation to Improve Area Diabetes Care
9. Freedom Meditech Receives JumpStart Investment
10. Lumension Security Receives Frost & Sullivan 2008 Global Market Penetration Leadership Award
11. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... company is unveiling its revolutionary new 2.0 version at the International Roofing Expo ... “put the power of the world's most advanced weather technology in the hands ...
(Date:2/10/2016)... Garland, TX (PRWEB) , ... February 10, 2016 ... ... the commencement of a master charity program created to assist the local community. ... closely with community leaders and nonprofit organizations in the area. Their goal is ...
(Date:2/10/2016)... ... , ... Ongoing news of the ravages of traumatic brain injury (TBI) among ... that takes a closer look at cases of TBI being managed by their members. ... among the aging population, and identifies the challenges associated with their care. , During ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... been awarded the prestigious Distinguished Emerald Club of the World award, as determined ... magazine, one of the most respected trade publications serving private clubs. , “We’d ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Jersey and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the ... Series D investment round on February 5, 2016. The ... Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, and ... SCP Vitalife Partners, Generali Financial Holdings and both the ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
Breaking Medicine Technology: